Aktienanalyse zu Corbus Pharmaceuticals Holdings Inc (CRBP)CRBPCorbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Corbus Pharmaceuticals is not a good buy right now. The current price is $3.915, which is significantly lower than the 52-week high of $12.88, indicating a downtrend. The RSI is at 21.889, suggesting that the stock is oversold, but this could also indicate continued weakness. Furthermore, the company has reported substantial losses, with a net income of -$35,037,000 in Q2 2026, and a forward P/E ratio of 0, indicating no earnings expected in the near term. The main risk is the high volatility, as indicated by an implied volatility of 327.95% and a historical volatility of 55.29%.

3 analysts cover CRBP: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 46.71.